Merrimack Pharmaceuticals Initiates Enrollment In A Phase 1 Study Of MM-121, An ErbB3 Antagonist Merrimack Pharmaceuticals, Inc. announced that the first patient has received an initial dose in a Phase 1 clinical study of the Company's first oncology product, MM-121, a fully human monoclonal antibody and a first-in-class therapeutic designed to block signaling of the ErbB3 receptor. ErbB3 is a receptor in the ErbB family, a pathway that plays a critical role in cancer signaling.
Source: www.medicalnewstoday.comDrug Information Association Innovation Forum To Highlight Latest Initiatives In Research & Development In The EU The Drug Information Association (DIA ) will host the first Innovation Forum (29-30 September; London, UK).
Source: www.medicalnewstoday.comPeregrine Pharmaceuticals Doses First Patient In Phase II Trial Of Bavituximab In Patients With Advanced Breast Cancer Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) announced that patient screening and dosing has begun in a Phase II trial designed to evaluate the safety and efficacy of bavituximab in combination with chemotherapy in patients with advanced breast cancer.
Source: www.medicalnewstoday.comCardiome And Astellas Announce Receipt Of FDA Approvable Letter For KYNAPID(TM) Cardiome Pharma Corp. (NASDAQ: CRME/TSX: COM) and its co-development partner Astellas Pharma US, Inc. ("Astellas") announced that they have received an action letter dated August 8, 2008 from the U.S.
Source: www.medicalnewstoday.comLAB Research To Host Safety Pharmacology Seminar In Madison, WI LAB Research Inc. ("LRI" or "LAB Research") (TSX: LRI), a rapidly growing global non-clinical contract research organization, announced that it will host an exhibitor's seminar titled "Study Design in Safety Pharmacology: Emerging Trends in Drug Development" at the upcoming 2008 Safety Pharmacology Society Meeting in Madison, WI. The informative seminar will take place on Tuesday, 23rd September from 7:00am - 8.00am. The session will be lead by Dr.
Source: www.medicalnewstoday.comAspirin, Acid Blocker A Day Keeps GI Bleeding At Bay For patients with clogged heart arteries who take long-term, low-dose aspirin to prevent a cardiac event, adding a stomach acid-blocking drug to their daily routine has been shown to reduce their risk for upper gastrointestinal bleeding an infrequent, but serious side-effect of regular aspirin use.
Source: www.medicalnewstoday.comFDA Warns Consumers About Potential Problems At Two Baltimore Pharmacies The U.S. Food and Drug Administration is warning consumers who filled
prescriptions at The
Medicine Shoppe pharmacies located at 8035A Liberty Road and 5900 Reisterstown Road in Baltimore that they may have received
drugs that were either expired or suspected counterfeit. The FDA is particularly concerned because a number of the
drugs are for serious diseases and could have an adverse effect on treatment.
Source: www.medicalnewstoday.com
# posted by Network @ 12:00 PM
